



Living Cell Technologies Ltd

COMPANY ANNOUNCEMENT

Results of Annual General Meeting held on 6 November 2008

ASX Announcement –6 November 2008, Adelaide Australia

The following voting results are in respect of the resolutions laid before Members at the Annual General Meeting of Living Cell Technologies Ltd held today is provided in accordance with Listing Rule 3.13.2 and section 251AA (2) of the Corporations Act.

The Chairman announced that he would vote all undirected proxies in favour of all resolutions.

The total number of proxy votes exercisable by all proxies validly appointed was 45,410,059.

Resolution 1 Remuneration Report (non binding):

“That the Remuneration Report required by section 300A of the Corporations Act, as contained in the Director’s Report of the Company, for the year ended 30 June 2008 be adopted.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
31,448,111	13,649,118	77,550	235,280

Resolution 2 Re-election of Mr David Collinson

“That Mr David Collinson retires by rotation in accordance with Clause 6.1 of the Company’s Constitution and being eligible, offers himself for re-election.”

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
45,158,779	-	16,000	235,280

Resolution 3 Re-election of Mr Simon O'Loughlin

To consider and, if thought fit, pass the following ordinary resolution:

"That Mr Simon O'Loughlin retires by rotation in accordance with Clause 6.1 of the Company's Constitution and being eligible, offers himself for re-election."

This resolution was passed following a poll, the results of which were:

FOR	AGAINST	ABSTAIN
36,630,579	25,610,891	16,000

Resolution 4 Approval of Issue of Options to Dr Robert Caspari in accordance with Listing Rule 10.11

"That approval be given pursuant to ASX Listing Rule 10.11 for the issue of 1,400,000 unlisted options over ordinary shares at a nil issue price. The exercise prices of these options to be as follows: in respect of 650,000 of the proposed options an exercise price of \$0.30 per share and in respect of 750,000 options an exercise price of \$0.40 per share to Dr Robert Caspari."

This resolution was passed unanimously on a show of hands.

Instructions in respect of the proxies were:

FOR	AGAINST	ABSTAIN	UNDIRECTED
31,427,661	13,679,568	67,550	235,280

By order of the board



Nick Geddes
Company Secretary

Investor and Media Relations
Rebecca Wilson
Buchan Consulting
P: +612 9237 2800
M: +61(0)417 382 391
rwilson@bcg.com.au

Investor and Media Relations
(U.S.) Leslie Wolf-Creutzfeldt
Grayling Global
Tel: +1-646-284-9472
lwolf-creutzfeldt@hfgcg.com

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of July 31, 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.